University of Texas Southwestern Medical Center, Dallas, TX
Santiago Olaechea, Alison Liu, Brandon Sarver, Christian Alvarez, L Anne Gilmore, Rodney E Infante, Puneeth Iyengar
Background: Cachexia, seen in more than a third of patients with non-small cell lung cancer (NSCLC), directly leads to functional and survival detriments. As screening and interventions for cachexia and NSCLC improve, deficits of healthcare access and quality among patients disadvantaged by race and socioeconomic factors must be addressed. Methods: Through retrospective and prospective data collection, we established a cohort of 957 patients diagnosed with stage IV NSCLC between 2014-2020 in Dallas, Texas. Presence of cachexia at diagnosis was determined using consensus criteria for substantial (5% for BMI≥20 and 2% for BMI < 20) unintentional weight loss in the 6 months leading to diagnosis. Analyses including multivariate logistic regression and log-rank testing evaluated for significant associations of variables with cachexia incidence and survival. Results: Black race and Hispanic ethnicity independently associated with more than a 70% increased risk of cachexia at NSCLC diagnosis (Table; P < 0.05). Inclusion of private insurance status as a covariate diminished this finding for Hispanic patients only. Black patients presented at younger ages than White patients (Kruskal-Wallis P =0.0012; T-test P = 0.0002), with an average difference of 3 years. Cachexia at diagnosis was a major predictor of survival, highlighting the importance of addressing differential cachexia risk across race/ethnicity. Conclusions: The elevated cachexia risk observed for Black patients independent of insurance status reveals broader causative factors of disparity. A lack of private insurance may be a primary contributor in Hispanic cachexia prevalence. Targeting these differences could mitigate survival detriments linked to cachexia in minority groups. Supported contributors in broader NSCLC outcome inequities include poor representation in trials substantiating USPSTF guidelines as well as preventable barriers to primary and preventative care. Our interpretation of NSCLC outcome disparity in the context of cachexia demonstrates further consequences of these deficits. Moreover, our findings suggest novel targets for health policy by highlighting the prevalence of undiagnosed unintentional weight loss in minority populations with late-stage NSCLC.
Parameter | Odds ratio (95% CI) | P-value |
---|---|---|
Age at diagnosis | 1.00 (.99-1.02) | .5675 |
Female Sex | .70 (.51-.96) | .0287 |
Race | ||
Non-Hispanic White | - | .0089 |
Black | 1.75 (1.21-2.54) | .0033 |
Asian | .91 (.45-1.81) | .7816 |
Hispanic | 1.72 (1.01-2.93) | .0477 |
Charlson comorbidity score | 1.00 (.95-1.06) | .8953 |
Pretreatment BMI | .98 (.95-1.00) | .1166 |
Alcohol use | .99 (.72-1.37) | .9588 |
Tobacco use | 1.63 (1.06-2.50) | .0257 |
Histology | ||
Adenocarcinoma | - | .2591 |
Squamous | 1.40 (.93-2.12) | .1084 |
Large Cell | 1.28 (.43-3.82) | .6591 |
Mixed | 1.46 (.87-2.44) | .1539 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
Funded by Conquer Cancer
2023 ASCO Quality Care Symposium
First Author: Simon Blanc
2023 ASCO Annual Meeting
First Author: Ethan Burns
2017 Palliative and Supportive Care in Oncology Symposium
First Author: Steven Lau
2023 ASCO Quality Care Symposium
First Author: Arjun Gupta